APO Research
Talk to an analyst

APO RESEARCH · REPORT

Herpes Simplex Virus (HSV) Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Herpes Simplex Virus (HSV) Vaccines Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchHerpes Simplex Virus (HSV) Vaccines Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Herpes Simplex Virus (HSV) Vaccines Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Herpes Simplex Virus (HSV) Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Herpes Simplex Virus (HSV) Vaccines Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Herpes Simplex Virus (HSV) Vaccines Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Herpes Simplex Virus (HSV) Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Herpes Simplex Virus (HSV) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Herpes Simplex Virus (HSV) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Herpes Simplex Virus (HSV) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Herpes Simplex Virus (HSV) Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Herpes Simplex Virus (HSV) Vaccines market include Sanofi, GlaxoSmithKline, Vical and Genocea Biosciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Herpes Simplex Virus (HSV) Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Herpes Simplex Virus (HSV) Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Herpes Simplex Virus (HSV) Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Herpes Simplex Virus (HSV) Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Herpes Simplex Virus (HSV) Vaccines Segment by Company

Sanofi

GlaxoSmithKline

Vical

Genocea Biosciences

Herpes Simplex Virus (HSV) Vaccines Segment by Type

VCL-HB01

HSV529

GEN-003

Others

Herpes Simplex Virus (HSV) Vaccines Segment by Application

HSV-1 (Oral Herpes)

HSV-2 (Genital Herpes)

Herpes Simplex Virus (HSV) Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Herpes Simplex Virus (HSV) Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Herpes Simplex Virus (HSV) Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Herpes Simplex Virus (HSV) Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Herpes Simplex Virus (HSV) Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Herpes Simplex Virus (HSV) Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Herpes Simplex Virus (HSV) Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Herpes Simplex Virus (HSV) Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Herpes Simplex Virus (HSV) Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Herpes Simplex Virus (HSV) Vaccines industry.

Chapter 3: Detailed analysis of Herpes Simplex Virus (HSV) Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Herpes Simplex Virus (HSV) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Herpes Simplex Virus (HSV) Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Herpes Simplex Virus (HSV) Vaccines Industry Trends Table 2. Herpes Simplex Virus (HSV) Vaccines Industry Drivers Table 3. Herpes Simplex Virus (HSV) Vaccines Industry Opportunities and Challenges Table 4. Herpes Simplex Virus (HSV) Vaccines Industry Restraints Table 5. Global Herpes Simplex Virus (HSV) Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Herpes Simplex Virus (HSV) Vaccines Revenue Share by Company (2021-2026) Table 7. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Company (k units) & (2021-2026) Table 8. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Herpes Simplex Virus (HSV) Vaccines Average Price (US$/unit) of Company (2021-2026) Table 10. Global Herpes Simplex Virus (HSV) Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Herpes Simplex Virus (HSV) Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Herpes Simplex Virus (HSV) Vaccines Company, Product Type & Application Table 13. Global Herpes Simplex Virus (HSV) Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Herpes Simplex Virus (HSV) Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of VCL-HB01 Table 18. Significant Companies of HSV529 Table 19. Significant Companies of GEN-003 Table 20. Significant Companies of Others Table 21. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Type (2021-2026) & (k units) Table 23. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Type (2027-2032) & (k units) Table 24. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share by Type (2021-2026) Table 25. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share by Type (2027-2032) Table 26. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type (2021-2026) Table 30. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type (2027-2032) Table 31. Significant Companies of HSV-1 (Oral Herpes) Table 32. Significant Companies of HSV-2 (Genital Herpes) Table 33. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Application (2021-2026) & (k units) Table 35. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Application (2027-2032) & (k units) Table 36. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share by Application (2021-2026) Table 37. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share by Application (2027-2032) Table 38. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application (2021-2026) Table 42. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application (2027-2032) Table 43. Global Herpes Simplex Virus (HSV) Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Herpes Simplex Virus (HSV) Vaccines Sales by Region (2021-2026) & (k units) Table 45. Global Herpes Simplex Virus (HSV) Vaccines Sales Market Share by Region (2021-2026) Table 46. Global Herpes Simplex Virus (HSV) Vaccines Sales by Region (2027-2032) & (k units) Table 47. Global Herpes Simplex Virus (HSV) Vaccines Sales Market Share by Region (2027-2032) Table 48. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Region (2021-2026) Table 51. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Region (2027-2032) Table 53. Global Herpes Simplex Virus (HSV) Vaccines Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Herpes Simplex Virus (HSV) Vaccines Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Herpes Simplex Virus (HSV) Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Herpes Simplex Virus (HSV) Vaccines Sales by Country (2021-2026) & (k units) Table 58. Global Herpes Simplex Virus (HSV) Vaccines Sales Market Share by Country (2021-2026) Table 59. Global Herpes Simplex Virus (HSV) Vaccines Sales by Country (2027-2032) & (k units) Table 60. Global Herpes Simplex Virus (HSV) Vaccines Sales Market Share by Country (2027-2032) Table 61. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Market Share by Country (2021-2026) Table 63. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Market Share by Country (2027-2032) Table 65. Sanofi Company Information Table 66. Sanofi Business Overview Table 67. Sanofi Herpes Simplex Virus (HSV) Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Sanofi Herpes Simplex Virus (HSV) Vaccines Product Portfolio Table 69. Sanofi Recent Development Table 70. GlaxoSmithKline Company Information Table 71. GlaxoSmithKline Business Overview Table 72. GlaxoSmithKline Herpes Simplex Virus (HSV) Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. GlaxoSmithKline Herpes Simplex Virus (HSV) Vaccines Product Portfolio Table 74. GlaxoSmithKline Recent Development Table 75. Vical Company Information Table 76. Vical Business Overview Table 77. Vical Herpes Simplex Virus (HSV) Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Vical Herpes Simplex Virus (HSV) Vaccines Product Portfolio Table 79. Vical Recent Development Table 80. Genocea Biosciences Company Information Table 81. Genocea Biosciences Business Overview Table 82. Genocea Biosciences Herpes Simplex Virus (HSV) Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Genocea Biosciences Herpes Simplex Virus (HSV) Vaccines Product Portfolio Table 84. Genocea Biosciences Recent Development Table 85. Key Raw Materials Table 86. Raw Materials Key Suppliers Table 87. Herpes Simplex Virus (HSV) Vaccines Distributors List Table 88. Herpes Simplex Virus (HSV) Vaccines Customers List Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Herpes Simplex Virus (HSV) Vaccines Product Image Figure 2. Global Herpes Simplex Virus (HSV) Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Herpes Simplex Virus (HSV) Vaccines Sales (2021-2032) & (k units) Figure 5. Global Herpes Simplex Virus (HSV) Vaccines Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Herpes Simplex Virus (HSV) Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. VCL-HB01 Image Figure 10. HSV529 Image Figure 11. GEN-003 Image Figure 12. Others Image Figure 13. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share by Type (2021-2032) Figure 16. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type (2021-2032) Figure 19. HSV-1 (Oral Herpes) Image Figure 20. HSV-2 (Genital Herpes) Image Figure 21. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share by Application (2021-2032) Figure 24. Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application (2021-2032) Figure 27. Global Herpes Simplex Virus (HSV) Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Herpes Simplex Virus (HSV) Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. North America Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. South America Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Herpes Simplex Virus (HSV) Vaccines Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Herpes Simplex Virus (HSV) Vaccines Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • VCL-HB01
  • HSV529
  • GEN-003
  • Others
Applications
  • HSV-1 (Oral Herpes)
  • HSV-2 (Genital Herpes)
Companies covered
  • Sanofi
  • GlaxoSmithKline
  • Vical
  • Genocea Biosciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Herpes Simplex Virus (HSV) Vaccines Market Dynamics
  1. 2.1 Herpes Simplex Virus (HSV) Vaccines Industry Trends
  2. 2.2 Herpes Simplex Virus (HSV) Vaccines Industry Drivers
  3. 2.3 Herpes Simplex Virus (HSV) Vaccines Industry Opportunities and Challenges
  4. 2.4 Herpes Simplex Virus (HSV) Vaccines Industry Restraints
3 Herpes Simplex Virus (HSV) Vaccines Market by Company
  1. 3.1 Global Herpes Simplex Virus (HSV) Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Herpes Simplex Virus (HSV) Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Herpes Simplex Virus (HSV) Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Herpes Simplex Virus (HSV) Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Herpes Simplex Virus (HSV) Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Herpes Simplex Virus (HSV) Vaccines Company Product Type and Application
  8. 3.8 Global Herpes Simplex Virus (HSV) Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Herpes Simplex Virus (HSV) Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Herpes Simplex Virus (HSV) Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Herpes Simplex Virus (HSV) Vaccines Market by Type
  1. 4.1 Herpes Simplex Virus (HSV) Vaccines Type Introduction
  2. 4.1.1 VCL-HB01
  3. 4.1.2 HSV529
  4. 4.1.3 GEN-003
  5. 4.1.4 Others
  6. 4.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Type
  7. 4.2.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Type
  11. 4.3.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Type (2021-2032)
  13. 4.3.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type (2021-2032)
5 Herpes Simplex Virus (HSV) Vaccines Market by Application
  1. 5.1 Herpes Simplex Virus (HSV) Vaccines Application Introduction
  2. 5.1.1 HSV-1 (Oral Herpes)
  3. 5.1.2 HSV-2 (Genital Herpes)
  4. 5.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Application
  5. 5.2.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Application
  9. 5.3.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application (2021-2032)
6 Herpes Simplex Virus (HSV) Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Herpes Simplex Virus (HSV) Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Herpes Simplex Virus (HSV) Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Herpes Simplex Virus (HSV) Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Herpes Simplex Virus (HSV) Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Herpes Simplex Virus (HSV) Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Herpes Simplex Virus (HSV) Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Country, 2025 VS 2032
7 Herpes Simplex Virus (HSV) Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Herpes Simplex Virus (HSV) Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Herpes Simplex Virus (HSV) Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Herpes Simplex Virus (HSV) Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Herpes Simplex Virus (HSV) Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Herpes Simplex Virus (HSV) Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Herpes Simplex Virus (HSV) Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Herpes Simplex Virus (HSV) Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Herpes Simplex Virus (HSV) Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Herpes Simplex Virus (HSV) Vaccines Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline Herpes Simplex Virus (HSV) Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Herpes Simplex Virus (HSV) Vaccines Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Vical
  14. 8.3.1 Vical Company Information
  15. 8.3.2 Vical Business Overview
  16. 8.3.3 Vical Herpes Simplex Virus (HSV) Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Vical Herpes Simplex Virus (HSV) Vaccines Product Portfolio
  18. 8.3.5 Vical Recent Developments
  19. 8.4 Genocea Biosciences
  20. 8.4.1 Genocea Biosciences Company Information
  21. 8.4.2 Genocea Biosciences Business Overview
  22. 8.4.3 Genocea Biosciences Herpes Simplex Virus (HSV) Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Genocea Biosciences Herpes Simplex Virus (HSV) Vaccines Product Portfolio
  24. 8.4.5 Genocea Biosciences Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Herpes Simplex Virus (HSV) Vaccines Value Chain Analysis
  2. 9.1.1 Herpes Simplex Virus (HSV) Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Herpes Simplex Virus (HSV) Vaccines Sales Mode & Process
  6. 9.2 Herpes Simplex Virus (HSV) Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Herpes Simplex Virus (HSV) Vaccines Distributors
  9. 9.2.3 Herpes Simplex Virus (HSV) Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst